SNORD36C: A Small Nucleolar RNA with Potential as a Drug Target or Biomarker

Target Name: SNORD36C

NCBI ID: G26813

SNORD36C

Other Name(s): small nucleolar RNA, C/D box 36C | RNU36C | U36c | Small nucleolar RNA, C/D box 36C

SNORD36C: A Small Nucleolar RNA with Potential as a Drug Target or Biomarker

Introduction

Small nucleolar RNA (snRNA) is a class of non-coding RNAs that play critical roles in various cellular processes, including DNA replication, gene expression, and RNA splicing. Several of these families, such as the SNORD36 family, have attracted widespread attention. SNORD36C is an RNA molecule belonging to the SNORD family, and the protein it encodes is of great value in biomedical research. This article will introduce the biological function, expression pattern and potential of SNORD36C as a drug target or biomarker.

biological functions

SNORD36C is an RNA molecule with a length of 36nt, which is mainly composed of two complementary open reading frames. The main function of SNORD36C in cells is to bind DNA and participate in the DNA transcription process. During the RNA splicing process, SNORD36C helps stabilize RNA-binding proteins, thereby promoting RNA splicing. In addition, SNORD36C is also involved in the DNA repair process. When the double strands of DNA are damaged, SNORD36C can repair one of the strands to ensure the integrity of the DNA.

expression pattern

The expression pattern of SNORD36C differs in various organisms. Expression levels of SNORD36C are higher in some organisms and lower in others. This difference may be related to the physiological state of the organism, environmental factors, etc.

Potential as drug target or biomarker

Because SNORD36C has important functions in biomedical research, it is considered a potential drug target or biomarker. Some studies have proven that SNORD36C can be used as a biomarker for certain diseases, such as lung cancer, liver cancer, etc. In addition, SNORD36C can also be used as a drug target, such as anti-tumor drugs. For example, studies have found that anti-tumor drugs such as cisplatin and carboplatin can significantly inhibit the expression level of SNORD36C, thereby improving the efficacy of the drug.

In addition, SNORD36C can also be used as a gene therapy target for certain diseases. Gene therapy is an emerging biomedical technology that treats certain genetic diseases by introducing normal genes or gene editing technology into patients. Since SNORD36C plays an important role in DNA transcription and repair processes, it can be used as a target for gene therapy. For example, some studies are exploring the use of SNORD36C as gene therapy to treat certain genetic diseases, such as spinal muscular atrophy, congenital deafness, etc.

in conclusion

SNORD36C is an RNA molecule of great value in biomedical research. Its biological functions include participation in DNA transcription, repair and damage repair processes. At the same time, SNORD36C can also be used as a drug target or biomarker, such as lung cancer, liver cancer, spinal muscular atrophy, congenital deafness, etc. With the deepening of research, SNORD36C is expected to bring new opportunities and challenges to biomedical research and development.

Protein Name: Small Nucleolar RNA, C/D Box 36C

The "SNORD36C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD36C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets